The Virgen de la Arrixaca Hospital, 30120 Murcia, Spain.
Faculty of Health Sciences, Department of Nursing, Physiotherapy and Medicine, University of Almeria, 04120 Almeria, Spain.
Int J Environ Res Public Health. 2023 Mar 6;20(5):4624. doi: 10.3390/ijerph20054624.
Multiple sclerosis (MS) is a chronic inflammatory neurodegenerative disease mediated by autoimmune reactions against myelin proteins and gangliosides in the grey and white matter of the brain and spinal cord. It is considered one of the most common neurological diseases of non-traumatic origin in young people, especially in women. Recent studies point to a possible association between MS and gut microbiota. Intestinal dysbiosis has been observed, as well as an alteration of short-chain fatty acid-producing bacteria, although clinical data remain scarce and inconclusive.
To conduct a systematic review on the relationship between gut microbiota and multiple sclerosis.
The systematic review was conducted in the first quarter of 2022. The articles included were selected and compiled from different electronic databases: PubMed, Scopus, ScienceDirect, Proquest, Cochrane, and CINAHL. The keywords used in the search were: "multiple sclerosis", "gut microbiota", and "microbiome".
12 articles were selected for the systematic review. Among the studies that analysed alpha and beta diversity, only three found significant differences with respect to the control. In terms of taxonomy, the data are contradictory, but confirm an alteration of the microbiota marked by a decrease in Firmicutes, Lachnospiraceae, , , , , , , , and and an increase in Bacteroidetes, , , and . As for short-chain fatty acids, in general, a decrease in short-chain fatty acids, in particular butyrate, was observed.
Gut microbiota dysbiosis was found in multiple sclerosis patients compared to controls. Most of the altered bacteria are short-chain fatty acid (SCFA)-producing, which could explain the chronic inflammation that characterises this disease. Therefore, future studies should consider the characterisation and manipulation of the multiple sclerosis-associated microbiome as a focus of both diagnostic and therapeutic strategies.
多发性硬化症(MS)是一种慢性炎症性神经退行性疾病,由针对大脑和脊髓灰质和白质中髓鞘蛋白和神经节苷脂的自身免疫反应介导。它被认为是年轻人中最常见的非创伤性起源的神经疾病之一,尤其是女性。最近的研究表明,多发性硬化症与肠道微生物群之间可能存在关联。已经观察到肠道菌群失调,以及短链脂肪酸产生菌的改变,尽管临床数据仍然很少且不确定。
对肠道微生物群与多发性硬化症之间的关系进行系统综述。
系统综述于 2022 年第一季度进行。从不同的电子数据库(PubMed、Scopus、ScienceDirect、Proquest、Cochrane 和 CINAHL)中选择和编译纳入的文章。搜索中使用的关键词是:“多发性硬化症”、“肠道微生物群”和“微生物组”。
共选择了 12 篇文章进行系统综述。在分析 alpha 和 beta 多样性的研究中,只有三项研究发现与对照组相比存在显著差异。就分类学而言,数据存在矛盾,但证实了微生物群的改变,表现为厚壁菌门、lachnospiraceae、、、、、、、和减少,拟杆菌门、、和增加。至于短链脂肪酸,一般来说,观察到短链脂肪酸,特别是丁酸盐减少。
与对照组相比,多发性硬化症患者存在肠道微生物群失调。大多数改变的细菌是短链脂肪酸(SCFA)产生菌,这可以解释这种疾病的慢性炎症。因此,未来的研究应考虑将多发性硬化症相关微生物群的特征和操纵作为诊断和治疗策略的重点。